Dear Editor, we would like to discuss on “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Results from an active pharmacovigilance study in central Italy.1 ” Through active surveillance reporting, Ripabelli et al. evaluated the adverse reactions following vaccination with the mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine in children aged 5 to 11 in central Italy.1 According to Ripabelli et al., only 5.7% and 3.9% of children reported adverse effects to doctors, and 17.6% and 15.8% of those children received treatment.1 The safety profile of mRNA BNT162b2 among children in Italy was initially reported by Ripabelli et al., who found that each dose of the vaccine was followed by brief, mild-to-moderate symptoms and no significant adverse effects.1
The surveillance data may provide important information about the vaccine’s safety. However, in each indexed instance with a clinical concern following immunization, it should talk about the procedure of verifying the precise underlying reason. It is important to take into account any hazards associated with the COVID-19 vaccination because co-morbidity can be difficult to manage.2 For instance, a person who received the COVID-19 vaccine may also have dengue.2 If a clinical issue develops after the immunization, this usually isn’t a good alternative. Prior to receiving a vaccine, it is essential to rule out any underlying illnesses or co-morbidities to prevent any clinical issues. Dengue can also contribute to hyposmia and transient audiovestibular.3 Another problem that needs to be taken into account is asymptomatic COVID-19. A previous asymptomatic COVID-19 cannot be ruled out by a basic history. Patients with SARS-Co-V2 may not be identified because they show no symptoms. Contrary to other illnesses, co-morbidity is occasionally thought to have adverse effects.4 Recent studies 5 have also connected recipient immunological responses to the COVID-19 with underlying genetic variance. Future studies should consider the diverse genetic background.
Funding Statement
The author(s) reported there is no funding associated with the work featured in this article.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Data availability statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
References
- 1.Ripabelli G, Sammarco ML, D’Amico A, De Dona R, Iafigliola M, Parente A, Samprati N, Santagata A, Adesso C, Natale A, et al. Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: results from an active pharmacovigilance study in central Italy. Hum Vaccin Immunother. 2022. Oct 31;2126668. Online ahead of print. doi: 10.1080/21645515.2022.2126668. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Kebayoon A, Wiwanitkit V.. Dengue after COVID-19 vaccination: possible and might be missed. Clin Appl Thromb Hemost. 2021. Jan-Dec;27:10760296211047229. doi: 10.1177/10760296211047229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Hilmy AI, Dey RK, Imad HA, Yoosuf AA, Nazeem A, Latheef AA. Coronavirus disease 2019 and dengue: two case reports. J Med Case Rep. 2021. Mar 26;15(1):171. doi: 10.1186/s13256-021-02707-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Joob B, Wiwanitkit V. Letter to the editor: Coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020. Mar;53(2):70. doi: 10.3961/jpmph.20.065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Čiučiulkaitė I, Möhlendick B, Thümmler L, Fisenkci N, Elsner C, Dittmer U, Siffert W, Lindemann M. GNB3 c.825c>t polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. Front Genet. 2022. Aug 29;13:932043. doi: 10.3389/fgene.2022.932043. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.